|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2.
|
Okuda K, Ohtsuki T, Obata H, et al:
Natural history of hepatocellular carcinoma and prognosis in
relation to treatment. Study of 850 patients. Cancer. 56:918–928.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Nagasue N, Yukaya H, Hamada T, Hirose S,
Kanashima R and Inokuchi K: The natural history of hepatocellular
carcinoma. A study of 100 untreated cases. Cancer. 54:1461–1465.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Llovet JM, Ricci S, Mazzaferro V, et al:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Calvet X, Bruix J, Gines P, et al:
Prognostic factors of hepatocellular carcinoma in the west: a
multivariate analysis in 206 patients. Hepatology. 12:753–760.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Attali P, Prod’Homme S, Pelletier G, et
al: Prognostic factors in patients with hepatocellular carcinoma.
Attempts for the selection of patients with prolonged survival.
Cancer. 59:2108–2111. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Poon D, Anderson BO, Chen LT, et al:
Management of hepatocellular carcinoma in Asia: consensus statement
from the Asian Oncology Summit 2009. Lancet Oncol. 10:1111–1118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Pang R and Poon RT: Angiogenesis and
antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.
242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Yamamoto A, Dhar DK, El-Assal ON, Igarashi
M, Tabara H and Nagasue N: Thymidine phosphorylase
(platelet-derived endothelial cell growth factor), microvessel
density and clinical outcome in hepatocellular carcinoma. J
Hepatol. 29:290–299. 1998. View Article : Google Scholar
|
|
10.
|
Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR
and Ma ZC: Microvessel density of hepatocellular carcinoma: its
relationship with prognosis. J Cancer Res Clin Oncol. 125:419–426.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
El-Assal ON, Yamanoi A, Soda Y, et al:
Clinical significance of microvessel density and vascular
endothelial growth factor expression in hepatocellular carcinoma
and surrounding liver: possible involvement of vascular endothelial
growth factor in the angiogenesis of cirrhotic liver. Hepatology.
27:1554–1562. 1998. View Article : Google Scholar
|
|
12.
|
Poon RT, Ng IO, Lau C, et al: Tumor
microvessel density as a predictor of recurrence after resection of
hepatocellular carcinoma: a prospective study. J Clin Oncol.
20:1775–1785. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Yang ZF and Poon RT: Vascular changes in
hepatocellular carcinoma. Anat Rec (Hoboken). 291:721–734. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
No authors listed:. The general rules for
the clinical and pathological study of primary liver cancer. Liver
Cancer Study Group of Japan. Jpn J Surg. 19:98–129. 1989.
View Article : Google Scholar
|
|
17.
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Llovet JM, Chen Y, Wurmbach E, et al: A
molecular signature to discriminate dysplastic nodules from early
hepatocellular carcinoma in HCV cirrhosis. Gastroenterology.
131:1758–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Colombat M, Paradis V, Bieche I, et al:
Quantitative RT-PCR in cirrhotic nodules reveals gene expression
changes associated with liver carcinogenesis. J Pathol.
201:260–267. 2003. View Article : Google Scholar
|
|
20.
|
Mouta Carreira C, Nasser SM, di Tomaso E,
et al: LYVE-1 is not restricted to the lymph vessels: expression in
normal liver blood sinusoids and down-regulation in human liver
cancer and cirrhosis. Cancer Res. 61:8079–8084. 2001.PubMed/NCBI
|
|
21.
|
Arimoto J, Ikura Y, Suekane T, et al:
Expression of LYVE-1 in sinusoidal endothelium is reduced in
chronically inflamed human livers. J Gastroenterol. 45:317–325.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ko S, Nakajima Y, Kanehiro H, et al:
Significant influence of accompanying chronic hepatitis status on
recurrence of hepatocellular carcinoma after hepatectomy. Result of
multivariate analysis. Ann Surg. 224:591–595. 1996. View Article : Google Scholar
|
|
23.
|
Johnson LA, Prevo R, Clasper S and Jackson
DG: Inflammation-induced uptake and degradation of the lymphatic
endothelial hyaluronan receptor LYVE-1. J Biol Chem.
282:33671–33680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Katoh S, Miyagi T, Taniguchi H, et al:
Cutting edge: an inducible sialidase regulates the hyaluronic acid
binding ability of CD44-bearing human monocytes. J Immunol.
162:5058–5061. 1999.PubMed/NCBI
|
|
25.
|
Gee K, Kozlowski M and Kumar A: Tumor
necrosis factor-alpha induces functionally active
hyaluronan-adhesive CD44 by activating sialidase through p38
mitogen-activated protein kinase in lipopolysaccharide-stimulated
human monocytic cells. J Biol Chem. 278:37275–37287. 2003.
View Article : Google Scholar
|
|
26.
|
Prevo R, Banerji S, Ferguson D, Clasper S
and Jackson D: Mouse LYVE-1 is an endocytic receptor for hyaluronan
in lymphatic endothelium. J Biol Chem. 276:19420–19430. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Du Y, Liu Y, Wang Y, He Y, Yang C and Gao
F: LYVE-1 enhances the adhesion of HS-578T cells to COS-7 cells via
hyaluronan. Clin Invest Med. 34:E45–E54. 2011.PubMed/NCBI
|
|
28.
|
Hou WH, Liua IH, Huang SS and Huang JS:
CRSBP-1/LYVE-1 ligands stimulate contraction of the
CRSBP-1-associated ER network in lymphatic endothelial cells. FEBS
Lett. 586:1480–1487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Ramani P, Dungwa JV and May MT: LYVE-1
upregulation and lymphatic invasion correlate with adverse
prognostic factors and lymph node metastasis in neuroblastoma.
Virchows Arch. 460:183–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Qin Z, Dai L, Bratoeva M, Slomiany MG,
Toole BP and Parsons C: Cooperative roles for emmprin and LYVE-1 in
the regulation of chemoresistance for primary effusion lymphoma.
Leukemia. 25:1598–1609. 2011. View Article : Google Scholar : PubMed/NCBI
|
